Johnson & Johnson (JNJ)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $687.89B
Last updated: Nov 17, 2026 at 11:06 AM ET
Johnson & Johnson (JNJ) Earnings: Report Dates and Results
Johnson & Johnson (JNJ) is confirmed to report earnings on Jan 26, 2027, after the close. In the quarter ended Sep 30, 2026, Johnson & Johnson reported EPS of $2.59, above the $2.53 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
JNJ has a confirmed report date of Jan 26, 2027, after the close. Analysts' consensus for the quarter ending Dec 31, 2026 is 19.5% above the $2.46 reported for the quarter ended Dec 31, 2025.
JNJ Earnings Call
The latest JNJ earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, JNJ beat 39 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $25.40B, up 5.9% from $23.99B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.59 | $2.53 | $2.31 - $2.81 | +2.37% | Beat | -7.5% | 13 | 0 up, 0 down | Oct 13, 2026 | $25.40B |
| Jun 30, 2026 | $2.90 | $2.84 | $2.65 - $3.00 | +2.11% | Beat | +4.7% | 17 | 0 up, 2 down | Jul 15, 2026 | $25.31B |
| Mar 31, 2026 | $2.70 | $2.68 | $2.14 - $2.89 | +0.75% | Beat | -2.5% | 18 | 2 up, 4 down | Apr 14, 2026 | $24.06B |
| Dec 31, 2025 | $2.46 | $2.46 | $2.37 - $2.57 | 0.00% | In line | +20.6% | 20 | 0 up, 12 down | Jan 21, 2026 | $24.56B |
| Sep 30, 2025 | $2.80 | $2.76 | $2.65 - $2.84 | +1.45% | Beat | +15.7% | 19 | 3 up, 2 down | Oct 14, 2025 | $23.99B |
| Jun 30, 2025 | $2.77 | $2.68 | $2.56 - $2.99 | +3.36% | Beat | -1.8% | 18 | N/A | Jul 16, 2025 | $23.74B |
| Mar 31, 2025 | $2.77 | $2.58 | $2.40 - $2.84 | +7.36% | Beat | +2.2% | 17 | 1 up, 7 down | Apr 15, 2025 | $21.89B |
| Dec 31, 2024 | $2.04 | $2.01 | $1.90 - $2.36 | +1.49% | Beat | -10.9% | 19 | 3 up, 2 down | Jan 22, 2025 | $22.52B |
| Sep 30, 2024 | $2.42 | $2.21 | $1.99 - $2.42 | +9.50% | Beat | -9.0% | 14 | 5 up, 1 down | Oct 15, 2024 | $22.47B |
| Jun 30, 2024 | $2.82 | $2.70 | $2.61 - $2.75 | +4.44% | Beat | +0.7% | 15 | 3 up, 0 down | Jul 17, 2024 | $22.45B |
| Mar 31, 2024 | $2.71 | $2.65 | $2.56 - $2.74 | +2.26% | Beat | +1.1% | 15 | 4 up, 1 down | Apr 16, 2024 | $21.38B |
| Dec 31, 2023 | $2.29 | $2.28 | $2.25 - $2.31 | +0.44% | Beat | -2.6% | 15 | 2 up, 1 down | Jan 23, 2024 | $21.39B |
| Sep 30, 2023 | $2.66 | $2.52 | N/A | +5.56% | Beat | +4.3% | 15 | 4 up, 1 down | Oct 17, 2023 | $21.35B |
| Jun 30, 2023 | $2.80 | $2.62 | $2.54 - $2.69 | +6.87% | Beat | +8.1% | 17 | 2 up, 1 down | Jul 20, 2023 | $21.52B |
| Mar 31, 2023 | $2.68 | $2.50 | $2.34 - $2.59 | +7.20% | Beat | +0.4% | 16 | 2 up, 1 down | Apr 18, 2023 | $20.89B |
| Dec 31, 2022 | $2.35 | $2.24 | $2.19 - $2.26 | +4.91% | Beat | +10.3% | 14 | 2 up, 1 down | Jan 24, 2023 | $12.55B |
| Sep 30, 2022 | $2.55 | $2.49 | $2.21 - $2.64 | +2.41% | Beat | -1.9% | 14 | 1 up, 1 down | Oct 18, 2022 | $20.00B |
| Jun 30, 2022 | $2.59 | $2.55 | $2.41 - $2.70 | +1.57% | Beat | +4.4% | 14 | 0 up, 0 down | Jul 19, 2022 | $24.02B |
| Mar 31, 2022 | $2.67 | $2.57 | $2.16 - $2.77 | +3.89% | Beat | +3.1% | 14 | 2 up, 4 down | Apr 19, 2022 | $23.43B |
| Dec 31, 2021 | $2.13 | $2.12 | $2.01 - $2.15 | +0.47% | Beat | +14.5% | 14 | 0 up, 0 down | Jan 25, 2022 | $9.77B |
| Sep 30, 2021 | $2.60 | $2.35 | $2.23 - $2.52 | +10.64% | Beat | +18.2% | 14 | N/A | Oct 19, 2021 | $23.34B |
| Jun 30, 2021 | $2.48 | $2.28 | $2.17 - $2.43 | +8.77% | Beat | +48.5% | 12 | N/A | Jul 21, 2021 | $23.31B |
| Mar 31, 2021 | $2.59 | $2.35 | $2.20 - $2.59 | +10.21% | Beat | +12.6% | 15 | N/A | Apr 20, 2021 | $22.32B |
| Dec 31, 2020 | $1.86 | $1.83 | $1.76 - $1.89 | +1.64% | Beat | -1.1% | 15 | N/A | Jan 26, 2021 | $22.48B |
| Sep 30, 2020 | $2.20 | $1.98 | $1.79 - $2.13 | +11.11% | Beat | +3.8% | 15 | N/A | Oct 13, 2020 | $21.08B |
| Jun 30, 2020 | $1.67 | $1.51 | $1.33 - $1.69 | +10.60% | Beat | -35.3% | 16 | N/A | Jul 16, 2020 | $18.34B |
| Mar 31, 2020 | $2.30 | $2.00 | $1.75 - $2.19 | +15.00% | Beat | +9.5% | 13 | N/A | Apr 14, 2020 | $20.69B |
| Dec 31, 2019 | $1.88 | $1.87 | $1.82 - $1.94 | +0.53% | Beat | -4.6% | 15 | N/A | Jan 22, 2020 | $20.75B |
| Sep 30, 2019 | $2.12 | $2.01 | $1.97 - $2.06 | +5.47% | Beat | +3.4% | 16 | N/A | Oct 15, 2019 | $20.73B |
| Jun 30, 2019 | $2.58 | $2.44 | $2.30 - $2.66 | +5.74% | Beat | +22.9% | 17 | N/A | Jul 16, 2019 | $20.56B |
| Mar 31, 2019 | $2.10 | $2.04 | $1.95 - $2.17 | +2.94% | Beat | +1.9% | 16 | N/A | Apr 16, 2019 | $20.02B |
| Dec 31, 2018 | $1.97 | $1.95 | $1.93 - $1.97 | +1.03% | Beat | +13.2% | 16 | N/A | Jan 22, 2019 | $20.39B |
| Sep 30, 2018 | $2.05 | $2.03 | $1.97 - $2.07 | +0.99% | Beat | +7.9% | 16 | N/A | Oct 16, 2018 | $20.35B |
| Jun 30, 2018 | $2.10 | $2.07 | $2.03 - $2.25 | +1.45% | Beat | +14.8% | 18 | N/A | Jul 17, 2018 | $20.83B |
| Mar 31, 2018 | $2.06 | $2.00 | $1.76 - $2.19 | +3.00% | Beat | +12.6% | 18 | N/A | Apr 17, 2018 | $20.01B |
| Dec 31, 2017 | $1.74 | $1.72 | $1.69 - $1.75 | +1.16% | Beat | +10.1% | 19 | N/A | Jan 23, 2018 | $20.20B |
| Sep 30, 2017 | $1.90 | $1.80 | $1.73 - $1.85 | +5.56% | Beat | +13.1% | 20 | N/A | Oct 17, 2017 | $19.65B |
| Jun 30, 2017 | $1.83 | $1.79 | $1.74 - $1.86 | +2.23% | Beat | +5.2% | 18 | N/A | Jul 18, 2017 | $18.84B |
| Mar 31, 2017 | $1.83 | $1.77 | N/A | +3.39% | Beat | +8.9% | N/A | N/A | Apr 18, 2017 | $17.77B |
| Dec 31, 2016 | $1.58 | $1.56 | N/A | +1.28% | Beat | +9.7% | N/A | N/A | Jan 24, 2017 | $18.11B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $10.80, up 8.1% from the year before. It was $6.68 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $10.80 | +8.1% |
| Dec 31, 2024 | $9.99 | -4.2% |
| Dec 31, 2023 | $10.43 | +2.7% |
| Dec 31, 2022 | $10.16 | +3.7% |
| Dec 31, 2021 | $9.80 | +22.0% |
| Dec 31, 2020 | $8.03 | -7.5% |
| Dec 31, 2019 | $8.68 | +6.1% |
| Dec 31, 2018 | $8.18 | +12.1% |
| Dec 31, 2017 | $7.30 | +9.3% |
| Dec 31, 2016 | $6.68 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,200 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,229 | 16 | |
| 2026Q2 | Jun 30, 2026 | 9,209 | 16 | |
| 2026Q1 | Mar 31, 2026 | 8,906 | 16 | |
| 2025Q4 | Dec 31, 2025 | 10,852 | 16 | |
| 2025Q3 | Sep 30, 2025 | 11,077 | 18 | |
| 2025Q2 | Jun 30, 2025 | 2,758 | 8 | |
| 2025Q1 | Mar 31, 2025 | 8,174 | 16 | |
| 2024Q4 | Dec 31, 2024 | 9,746 | 15 |
2026Q3 Earnings Call
Opening remarks
Ryan Koors Vice President, Investor Relations Hello, everyone. This is Ryan Koors, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of business results for the third quarter of 2026 and our financial outlook for the full year. First, a few logistics. As a reminder, today's presentation and associated schedules are available on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position, and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events using the information available as of the date of this recording. They are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. The description of these risks, uncertainties, and other factors can be found in our SEC filings, including our 2025 Form 10-K, which is available at investor.jnj.com and on the SEC's website. Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships. Moving to today's agenda, Joaquin Duato, our Chairman and CEO, will discuss our business performance and growth drivers. I will then review the third-quarter sales and P&L results. Joe Wolk, our CFO, will then close by sharing an overview of our capital allocation priorities and updated guidance for 2026. Tom Cavanagh, Executive Vice President, Worldwide Chairman, Innovative Medicine; John Reed, Executive Vice President, Innovative Medicine Research and Development; and Timothy Schmid, Executive Vice President, Worldwide Chairman, MedTech, will be joining us for Q&A. To ensure we provide enough time to address your questions, we anticipate the webcast will last approximately 60 minutes. With that, I will now turn the call over to Joaquin.
Joaquin Duato Chairman and CEO Thank you, Ryan, and good morning, everyone. Our strong performance in the third quarter reinforces our confidence in 2026 as a year of accelerated growth and impact for Johnson & Johnson. In Q3, we reported operational sales growth of 6%, ahead of analyst consensus, and increased sequential growth compared to the second quarter. With six strategic focus areas—oncology, immunology, neuroscience, cardiovascular, surgery, and vision—we are leading in areas of higher medical need where innovation can make the greatest difference for patients. Our powerful combination of Innovative Medicine and MedTech expertise strengthens our competitiveness. Twenty-nine of our products and platforms now generate at least $1 billion in annual sales. Our marketed portfolio continues to perform. Our launches are gaining significant traction, and we are advancing our new product pipeline that will sustain our growth into the next decade.
Frequently Asked Questions About JNJ
When is Johnson & Johnson's next earnings date?
Johnson & Johnson's next earnings report is confirmed for Jan 26, 2027, after the close.
Did JNJ beat earnings estimates last quarter?
Yes. Johnson & Johnson reported EPS of $2.59 for the quarter ended Sep 30, 2026, above the $2.53 estimate, a 2.37% surprise.
What EPS do analysts expect from JNJ next quarter?
The consensus EPS estimate for Johnson & Johnson for the quarter ending Dec 31, 2026 is $2.94 from 18 analysts, with estimates from $2.80 to $3.10.
How often does JNJ beat earnings estimates?
Johnson & Johnson beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +2.36%.
Does JNJ report before or after the market opens?
Johnson & Johnson is confirmed to report on Jan 26, 2027, after the market closes.
JNJ pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts